Arch Therapeutics, Inc. (ARTH) SEC Filing 8-K Material Event for the period ending Monday, August 30, 2021

Arch Therapeutics, Inc.

CIK: 1537561 Ticker: ARTH

View differences made from one to another to evaluate Arch Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Arch Therapeutics, Inc..


Assess how Arch Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Arch Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Arch Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ARTH
CIK: 1537561
Form Type: 8-K Corporate News
Accession Number: 0001104659-21-112286
Submitted to the SEC: Thu Sep 02 2021 10:16:59 AM EST
Accepted by the SEC: Thu Sep 02 2021
Period: Monday, August 30, 2021
Industry: Surgical And Medical Instruments And Apparatus
  1. Financial Exhibit
  2. Other Events
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: